Cambrex, a small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has named Tom Loewald as its chief executive officer and a member of the company’s board of directors, effective September 7, 2020. As previously announced, in the interim, the company will be led by an Office of the CEO comprised of Wayne Hewett, chairman of the board, Robert Green, executive vice president and chief financial officer, and Samantha Hanley, senior vice president and general counsel.
 

Mr. Loewald is a 15-year veteran of Thermo Fisher Scientific, where he served in several senior executive roles during his tenure, including chief commercial officer, president of the analytical instruments group, president of the laboratory products group and president of the laboratory equipment division. He currently serves as president of the flexibles division of ProAmpac, a leading flexible packaging manufacturer. Earlier in his career he held leadership positions at Tyco International and General Electric. Mr. Loewald currently serves on the board of directors of Harvard BioScience, a global developer, manufacturer and marketer of a broad range of solutions to advance life science.
 
“Tom’s deep knowledge of life sciences and manufacturing, and strong commercial, operating and financial focus, make him the ideal leader for Cambrex as we approach this phase of accelerated growth,” said Cambrex’s chairman Mr. Hewett. “We are confident that he will be an excellent fit for the company’s customer-centric culture and look forward to supporting him and the entire team on the exciting road ahead.”